INTRODUCTION
The experimental treatment of intracranial vascular disorders, primarily inaccessible and inoperable deep arteriovenous malformations (AVM), including carotid-cavernous fistulas (CCF), using stereotactically-directed heavy charged particle or ganuna bean focal irradiation in the brain is new, and holds significant promise for alleviating the risks of morbidity and of mortality in selected neurological patients (1) (2) (3) (4) (5) . The 1ntracranial deep AVMs have three important features. (lJ They have a significant incidence of spontaneous intracranial hemorrhage that leads either to severe morbidity or to mortality.
(2) Even in the absence of serious hemorrhage, nevertheless, due to progressive 'I'"" cerebral ischemia, patients develop progressive and irreversible neurological deficits, including motor and sensory dysfunctions, mental deterioration and blindness. ( 1) The abnormal intracerebral blood flow dynamics, mass effect, and brain ischemia frequently induce seizures, which are refractory to medication ·:, . 1 because of the chronic venous hypertension in the brain. The present report describes the development of a charged-particle hel itJTI-ion beam for stereotactically-directed Bragg peak irradiation of brain disorders in patients at the Donner Laboratory and, particularly, for application to treatment of deep AVMs.
The physical properties of heavy charged-particle beams offer some unique advantages in neuroscience research. The beams have Bragg ionization peaks with increased release of energy at the end of their range, minimal scattering, finite range and small range straggling {7). Investigations using proton, deuteron and he 1 i um-i on beams have shown that these beams can be used effectively in brain research in animals and in treatment of selected human .brain disorders {5, [8] [9] [10] [11] . The 184-inch Synchrocyclotron at the University of California, Berkeley, was first used for biological studies in 1948 {8) and for the treatment of. patients in 1954 (9) using proton or deuteron beams. The helium-ion beam from the 184-inch Synchrocyclotron has been used since 1958 for stereotactic irradiation of the pituitary gland in patients with endocrine and metabolic disorders; here, the plateau portion of the Bragg curve has been utilized {12-14). In addition, other sites in selected neurological or cancer patients have been irradiated using the high-energy plateau portion {15) of the Bragg peak {12,16,17) of the helium-ion beam. In 1975, following modifications to produce a bean for large-field cancer radiotherapy {18), a heavy particle cancer radiotherapy progran was initiated {17,19). For cancer therapy, in this configuration, field sizes as large as 30 em circles are used with residual ranges as great as 26 em. The capability for treating eye tumors {ocular melanomas) was later added to the readily available beam conditions (20) . This radiotherapy setup is for bean di aneters less than 2.5 em and residual ranges less than 3 em.
In 1980, we began investigations on stereotactic radiosurgery {1,4,21) in the central nervous system using the Bragg peak of the hel i urn-ion bean at the
• 184-inch Synchrocyclotron, primarily for intracranial vascular disorders {22).
The use of stereotactically-directed focal radiation beams for the treatment of inoperable intracranial deep arteriovenous malformations has been applied by Leksell and his colleagues (1,2) using multiple cobalt-60 gamma beams at the Karolinska Sjukhuset, by Kjellberg and colleagues (3) using the proton beam at the Harvard cyclotron, and by Barcia-Saloria (23) using a cobalt therapy unit at the University of Valencia, Spain {24).
Recent work has shown the feasibility of using high energy X-ray machines (25, 26) .
To perform intracranial stereotactic radiosurgery with the Bragg peak, it was necessary to develop a small field beamline configuration at the 184-inch Synchrocyclotron, since the existing stereotactic irradiation facility used for pituitary irradiation of patients (27) was not optimized for use with the Bragg peak. The major requirements in developing a hel i tJTI-ion beam for stereotactic radiosurgery were: (1) uniform field between 10 and 40 mm in diameter; (2) variable depth of penetration between 40 and 140 mm; (3) stopping region for the primary ions that could be broadened up to 40 mm; (4) sharply defined lateral and distal borders; and (5) dose-rate greater than 2 Gy/min.
METHODS ANO MATERIALS
The range in water of the 230-MeV/u hel i tJTI-ion beam at the 184-inch Synchrocyclotron is 316 mm. This range is greater than that needed to reach any intracranial target; therefore, it is necessary to degrade the beam energy in order to obtain the required residual range. This must be done in a manner that minimizes the beam straggling, the multiple scattering and the loss of the primary ions due to nuclear interactions {28).
Beam Edge Sharpness
To achieve a sharp lateral edge to the beam and, thus, to the treatment voltJTle, the penumbra of the beam is kept as small as is practical, consistent with all other requirements, and the beam passing through the final collimator is kept essentially parallel. These conditions are met by placing all the beam degrading material about 3.8 m upstream of the final beam collimator (Fig. 1) .
The beam striking the degrader is approximately 30 mm by 40 mm (FWHM).
Immediately after the degrading material, the beam is collimated by a 22 mm brass collimator. This geometry produces a geometric penumbra of 0. The energy degradation is accomplished with a composite absorber consisting of 153 mm of polyethylene followed by 3.4 mm of copper. While this combination of degraders may not be the only way to achieve the desired goal, it was the ..
only one we tested since we achieved a satisfactory result with this approach. 
RESULTS
Depth-dose measurements with the parallel plate ionization chamber indicated a maximliTI range to the Bragg peak of 145 mm in water; this included the wall thickness of the water column (Fig. 2) . The dose beyond the Bragg peak decreased from 90 percent of the maximum to 10 percent within 6 mm. The peak-to-plateau ratio was 3.09.
The depth-dose distribution with the stopping region broadened by 21.6 mm is shown in Fig. 3 . The beam profile was measured with a diode and with X-ray film at the midpoint of a 27 mm broadened stopping region (Fig. 4) . The lateral edge of the beam is sharpest at all depths when the final collimator is placed in contact with the entrance surface of the polyethylene or water phantom (Table 1) .
A dose-rate of 4.0 Gy/min is regularly and uniformly delivered in the Reference to a company or product name does not imply approval or recommendation of the product by the University of California or the U.S. Department of Energy to the exclusion of others that may be suitable.
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